Phaseline

Targets › TXNIP

TXNIP (Thioredoxin-interacting protein): drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Dec 2026.

May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability. Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm (By similarity). (UniProt, Q9H3M7)

Open in Phaseline: the race on TXNIP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TIXiMEDTIX100
thioredoxin-interacting protein (TXNIP) inhibitor
TXNIPPhase 1Healthy; Health Adult SubjectsDec 2026

Conditions

Healthy (1) Health Adult Subjects (1)

Modalities

small molecule (1)

Companies

TIXiMED (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.